Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vesicular stomatitis virus glycoprotein (VSV-G) is the surface envelope glycoprotein of vesicular stomatitis virus (VSV), a rhabdovirus. VSV-G is a class III viral fusion protein responsible for mediating both receptor recognition (binding to cell surface molecules) and low pH-triggered membrane fusion, thereby enabling the virus to enter host cells. The protein functions as a trimer on the viral envelope and undergoes reversible, pH-dependent conformational changes during membrane fusion. VSV-G is notable in biotechnology, where it is widely used to pseudotype lentiviral and other viral vectors to broaden tropism and improve stability of gene delivery systems. It is not a human target nor a conventional drug target, but is highly relevant as a tool and sometimes as a safety concern in gene therapy and vaccine development.
For VSV-G pseudotyped vectors: mediates entry of recombinant vectors into target cells by binding broadly to cell surface phosphatidylserine and other receptors, then triggers membrane fusion upon acidification in endosomes. For potential antivirals: would block receptor binding or membrane fusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vesicular stomatitis virus glycoprotein (VSV-G).